Novartis Warns MS Pill Linked to Two Brain Infections, FDA Says

Novartis AG must disclose that its pill to treat multiple sclerosis, Gilenya, has been linked to as many as two cases of brain infection, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.